XJPX4584
Market cap21mUSD
Jan 17, Last price
106.00JPY
1D
0.95%
1Q
-7.83%
Jan 2017
-87.16%
IPO
-67.18%
Name
Kidswell Bio Corp
Chart & Performance
P/E
—
P/S
1.40
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
22.33%
Revenues
2.43b
-12.43%
Net income
-1.42b
L+116.31%
CFO
-454m
L-68.08%
Profile
Kidswell Bio Corporation develops pharmaceuticals for the treatment of rare and intractable diseases in Japan. Its pipeline products include GND-004 for the treatment of ophthalmic disease and oncology; GND-007 for the treatment of immunological disease; and antibodies for oncology. The company pipeline products also include GBS-001, GBS-004, and GBS-010 for oncology; GBS-005 for immunological diseases; GBS-007 and GBS-012 for ophthalmic disease; GBS-008 for infectious diseases; and GBS-011 for renal disease. In addition, its products also include GCT-101 for alveolar cleft; GCT-102 for congenital isolated hypoganglionosis; and other pipeline products for ophthalmologic diseases, cerebral palsy, peripheral nerve palsy, fracture, and spinal cord injury. The company was formerly known as Gene Techno Science Co.,Ltd. and changed its name to Kidswell Bio Corporation in July 2021. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 2,431,235 -12.43% | 2,776,240 76.92% | 1,569,231 57.47% | ||
Cost of revenue | 3,009,164 | 2,649,832 | 1,555,321 | ||
Unusual Expense (Income) | |||||
NOPBT | (577,929) | 126,408 | 13,910 | ||
NOPBT Margin | 4.55% | 0.89% | |||
Operating Taxes | 1,551 | 1,210 | 1,210 | ||
Tax Rate | 0.96% | 8.70% | |||
NOPAT | (579,480) | 125,198 | 12,700 | ||
Net income | (1,422,078) 116.31% | (657,434) 19.35% | (550,863) -44.99% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 992,883 | 36,592 | 369,083 | ||
BB yield | -18.60% | -0.45% | -2.60% | ||
| Debt | |||||
Debt current | 737,040 | 375,000 | 75,000 | ||
Long-term debt | 1,837,960 | 1,575,000 | 625,000 | ||
Deferred revenue | |||||
Other long-term liabilities | 40,890 | 30,421 | 31,261 | ||
Net debt | 205,371 | 709,620 | (632,934) | ||
| Cash flow | |||||
Cash from operating activities | (453,634) | (1,421,259) | (1,169,561) | ||
CAPEX | 453,634 | (160) | |||
Cash from investing activities | (28,825) | 526,509 | |||
Cash from financing activities | 1,617,883 | 1,356,312 | 369,083 | ||
FCF | 275,768 | (725,953) | (312,723) | ||
| Balance | |||||
Cash | 2,231,411 | 1,067,162 | 1,160,934 | ||
Long term investments | 138,218 | 173,218 | 172,000 | ||
Excess cash | 2,248,067 | 1,101,568 | 1,254,472 | ||
Stockholders' equity | (10,672,358) | (9,581,520) | (9,025,358) | ||
Invested Capital | 14,119,721 | 12,762,766 | 11,421,694 | ||
ROIC | 1.04% | 0.11% | |||
ROCE | 3.97% | 0.58% | |||
| EV | |||||
Common stock shares outstanding | 35,345 | 31,654 | 30,851 | ||
Price | 151.00 -41.02% | 256.00 -44.35% | 460.00 -8.73% | ||
Market cap | 5,337,081 -34.14% | 8,103,473 -42.90% | 14,191,595 -2.19% | ||
EV | 5,542,452 | 8,813,093 | 13,558,661 | ||
EBITDA | (577,008) | 127,340 | 16,210 | ||
EV/EBITDA | 69.21 | 836.44 | |||
Interest | 38,784 | 34,836 | 15,460 | ||
Interest/NOPBT | 27.56% | 111.14% | |||